As of November 6, 2026, Kyverna Therapeutics, Inc. is a publicly traded company (Nasdaq: KYTX); its largest reported holder is GordonMD Global Investments LP, with 7% on Schedule 13G of November 17, 2025, then Michael P. Rubin (6.1%). The largest insider holding is Fred Cohen, a director, with 4,545,651 shares (7.4% of shares outstanding), per Form 4 of May 29, 2026 (Schedule 13G, November 17, 2025).
Is this your company?
About to sign with, pay or invest in Kyverna Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Kyverna Therapeutics, Inc. a real, registered company?
- Kyverna Therapeutics, Inc. files with the SEC under CIK 1994702 (its SEC filings).
- Its shares are listed under the ticker KYTX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Emeryville, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Kyverna Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Gregory Martini, Chief Financial Officer (Form 8-K filed 2026-05-18). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Orin Hirschman (filed 2026-10-19).
Who are Kyverna Therapeutics, Inc.'s owners and officers?
Kyverna Therapeutics, Inc.: incorporated in Delaware; business address in Emeryville, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-10-19).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-11-07)
- : Executive Officer (Form D, 2023-11-07)
- : Executive Officer (Form D, 2023-11-07)
- : Executive Officer (Form D, 2023-11-07)
- : Executive Officer (Form D, 2023-11-07)
- : Director (Form D, 2023-11-07)
- : Director (Form D, 2023-11-07)
- : Director (Form D, 2023-11-07)
- : Director (Form D, 2023-11-07)
- : Director (Form D, 2023-11-07)
- : Director (Form D, 2023-11-07)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-19 | Orin Hirschman | 5.9% |
| Schedule 13G/A, 2026-08-14 | Bain Capital Life Sciences Opportunities Iii, LP | 4.75% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.1% |
| Schedule 13G/A, 2026-02-17 | Bain Capital Life Sciences Opportunities Iii, LP | 5.4% |
| Schedule 13G/A, 2026-02-17 | Michael P. Rubin | 6.1% |
| Schedule 13G/A, 2026-02-06 | Dr. Beth C. Seidenberg ("Seidenberg") | 7.8% |
| Schedule 13G, 2025-11-17 | Gordonmd Global Investments LP | 7% |
Questions about who owns Kyverna Therapeutics, Inc.
Who owns Kyverna Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Kyverna Therapeutics, Inc.: Dr. Beth C. Seidenberg ("Seidenberg") (7.8%, Schedule 13G/A, filed 2026-02-06), Gordonmd Global Investments LP (7%, Schedule 13G, filed 2025-11-17), Michael P. Rubin (6.1%, Schedule 13G/A, filed 2026-02-17), Orin Hirschman (5.9%, Schedule 13G, filed 2026-10-19) and Blackrock, Inc. (5.1%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Kyverna Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Kyverna Therapeutics, Inc. on this page are Dr. Beth C. Seidenberg ("Seidenberg") (7.8%), Gordonmd Global Investments LP (7%) and Michael P. Rubin (6.1%).
When did Dr. Beth C. Seidenberg ("Seidenberg") buy into Kyverna Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Dr. Beth C. Seidenberg ("Seidenberg") on this page is the Schedule 13G/A, filed 2026-02-06, reporting 7.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Kyverna Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Kyverna Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kyverna Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-05-18 | Gregory Martini | Chief Financial Officer | appointed | 2026-05-18 |
| Form 8-K, 2026-05-18 | Gregory Martini | appointed |
Which insiders own Kyverna Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 4,545,651 shares (7.4% of shares outstanding), 21,727 held directly and 4,523,924 indirectly (Form 4, 2026-05-29).
- , a director: 891,044 shares (1.4% of shares outstanding), 21,727 held directly and 869,317 indirectly (Form 4, 2026-05-29).
- Westlake BioPartners Opportunity Fund I, L.P., a 10% owner: 869,317 shares (1.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-22).
- Westlake BioPartners Opportunity GP I, LLC, a 10% owner: 869,317 shares (1.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-22).
- Westlake BioPartners GP I, LLC, a 10% owner: 869,317 shares (1.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-22).
Shares outstanding: 61,843,444 as of 2026-08-03, from the company's latest SEC cover page.
How much has Kyverna Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-11-07 | $152M | $152M |
Keep reading
More on Kyverna Therapeutics, Inc. and the records around it.
Kyverna Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes May 2026
Companies that share a holder
- GordonMD Global Investments LP also filed stake reports on 1 other company: Pyxis Oncology, Inc. (Oct 2026)
- Bain Capital Life Sciences Opportunities III, LP also filed stake reports on 2 other companies: CABALETTA BIO, INC. (Aug 2026), CENTURY THERAPEUTICS, INC. (Nov 2025)
- Westlake BioPartners Fund I, L.P. ("Westlake Fund I") also filed stake reports on 2 other companies: Electra Therapeutics, Inc. (Oct 2026), Latigo Biotherapeutics, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/kyverna-therapeutics